Pharmacokinetic and Lipidomic Assessment of the In Vivo Effects of Parishin A-Isorhynchophylline in Rat Migraine Models

Abstract EN

Migraine is a chronic brain disease that leads to periodic neurological attacks.

Parishin A and isorhynchophylline (PI) is the active monomer component extracted from the traditional antimigraine Chinese medicinal combination of Gastrodia and Uncaria, respectively.

In this study, using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) technology, we performed pharmacokinetic and lipidomic study on migraine model rats after administration of PI.

For the detection of the compounds in plasma, AB Sciex Triple Quad™ 4500 was applied for quantitative analysis, and the COSMOSIL C18 column (2.1 × 100 mm, 2.6 μm) was used for separation.

Isorhynchophylline (ISO: m/z 384.8–241.2) and its main metabolite rhynchophylline (RHY: m/z 384.8–160.2) were simultaneously detected under positive ion modes.

Besides, parishin A (PA: m/z 995.1–726.9) and its main metabolite gastrodin (GAS: m/z 331.1–123.0) were simultaneously detected with negative ion modes.

For the analysis of endogenous lipid components, Dionex Ultimate 3000 (UHPLC) Thermo Orbitrap Elite was applied for the detection, and the Waters UPLCRBEH C18 column (1.7 μm 100 ∗ 2.1 mm) was used for separation.

Chloroform/methanol (2 : 1, v : v) was used for extraction.

The results demonstrated that PI exists significant difference in metabolism between single- and coadministration and can regulate lipid levels associated with migraine.